Technical analysis for Greenwich Lifesciences Inc. GLSI including support levels resistance levels and stop losses for GLSI ...
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other ...
Warszawa (2) Wojskowy Instytut Medyczny,Państwowy Instytut Badawczy Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie ...
Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock, indicating that insiders' optimism about the company's prospects ...
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Greenwich LifeSciences, Inc. STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback